MedTrace Logo

Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience

NCT07777965 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-08-21

No results posted yet for this study

Summary

The purpose of the present study is to assess prospectively the abuse potential of gabapentin compared to placebo and alprazolam in healthy non-drug-dependent recreational sedative drug users under fasted condition.

Conditions

  • Healthy Non-dependent, Recreational Sedative Users

Interventions

DRUG

Alprazolam (Xanax)

2mg

DRUG

Placebo

placebo

DRUG

Gabapentin (Neurontin® (Registered Trademark))

1200mg

DRUG

Gabapentin (Neurontin® (Registered Trademark))

1800mg

Sponsors & Collaborators

  • Dr. Vince Clinical Research

    collaborator OTHER

  • Viatris Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-18
Primary Completion
2026-11-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07777965 on ClinicalTrials.gov